ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent

ACRS 2.425

+3.6%

2:46 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: BioHero	9/24/2019 11:47:20 AM
	of 23

With $115 Million Cash or untill late 2021 and more Cash + Royalties from partnering of their commercial and pipeline assets (expected soon) and approval of the warts drug ACRS could reach profitability and may never needs Cash again IF they can reduce the burn-rate to $10 million or lower per Quarter which is achievable . Whatever this stock is a MEGA BUYING OPP ahead of the second Phase 3 readout and Partnering expected during Q4 .GL Aclaris Therapeutics to Hold R&D Day investor.aclaristx.com Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will host an R&D day for analysts and investors focused on its pipeline of novel drug candidates for immuno-inflammatory diseases on Friday, September 27, 2019 from 8:00 AM to 11:00 AM in New York, New York.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next